LaVoieHealthScience President and CEO, Donna LaVoie, contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations. Donna discusses what makes strategic communications and investor relations in biotech different from other industries. The communications function is often reliant on the entire strategic leadership team in a startup biotech. From her experience, Donna explains how nuances in biotech communications require a unique skillset to articulate a scientific and clinical/commercial story while balancing important strategic imperatives like time sensitive information and regulatory processes.
Read the full article on the O’Dwyer’s PR News website.
LaVoieHealthScience offers integrated communications in life sciences, with specializations in strategy consulting, investor relations and corporate communications, and public relations and marketing.